[1] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. [2] Cooper JS, Porter K, Mallin K, et al.National Cancer Database report on cancer of the head and neck: 10-year update[J]. Head Neck, 2009, 31(6): 748-758. [3] Argiris A, Karamouzis MV, Raben D, et al.Head and neck cancer[J]. Lancet, 2008, 371(9625): 1695-1709. [4] Warnakulasuriya S.Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival[J]. Oral Oncol, 2010, 46(6):407-410. [5] Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene, 2010, 29(5): 625-634.=-9 [6] Balamurugan K.HIF-1 at the crossroads of hypoxia, inflammation, and cancer[J]. Int J Cancer, 2016, 138(5): 1058-1066. [7] Semenza GL.Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer, 2003, 3(10):721-732. [8] Zheng Y, Ni Y, Huang X, et al.Overexpression of HIF-1alpha indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis[J]. Oncol Lett, 2013, 5(4): 1285-1289. [9] Comito G, Calvani M, Giannoni E, et al.HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells[J]. Free Radic Biol Med, 2011, 51(4): 893-904. [10] Nakajima EC, Van Houten B.Metabolic symbiosis in cancer: refocusing the Warburg lens[J]. Mol Carcinog, 2013, 52(5): 329-337. [11] Grimm M, Munz A, Teriete P, et al.GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 117(6): 743-753. [12] Deng D, Xu C, Sun P, et al.Crystal structure of the human glucose transporter GLUT1[J]. Nature, 2014, 510(7503): 121-125. [13] Robey IF, Lien AD, Welsh SJ, et al.Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors[J]. Neoplasia, 2005, 7(4): 324-330. [14] Amann T, Maegdefrau U, Hartmann A, et al.GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis[J]. Am J Pathol, 2009, 174(4):1544-1552. [15] Oh S, Kim H, Nam K, et al.Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells[J]. BMB Rep, 2017, 50(3): 132-137. [16] Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality[J]. Sci Transl Med, 2011, 3(94): 94ra70. [17] Han S, Xu W, Wang Z, et al.Crosstalk between the HIF-1 and toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment[J]. Oncotarget, 2016, 7(25): 37773-37789. [18] Qian J, Wenguang X, Zhiyong W, et al.Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma[J]. Tumour Biol, 2016, 37(8): 10815-10820. [19] Kizaka-Kondoh S, Tanaka S, Harada H, et al.The HIF-1-active microenvironment: an environmental target for cancer therapy[J]. Adv Drug Deliv Rev, 2009, 61(7-8): 623-632. [20] Song K, Li M, Xu XJ, et al.HIF-1alpha and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia[J]. Asian Pac J Cancer Prev, 2014, 15(4): 1823-1829. [21] Xiao H, Wang J, Yan W, et al.GLUT1 regulates cell glycolysis and proliferation in prostate cancer[J]. Prostate, 2018, 78(2): 86-94. [22] Li CX, Sun JL, Gong ZC, et al.Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: a prisma-compliant meta-analysis[J]. Medicine(Baltimore), 2016, 95(45): e5324. [23] Kunkel M, Reichert TE, Benz P, et al.Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma[J]. Cancer, 2003, 94(4): 1015-1024. [24] Wellberg EA, Johnson S, Finlay-Schultz J, et al.The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis[J]. Breast Cancer Res, 2016, 18(1): 131-146. [25] Zhao X, Lu C, Chu W, et al.MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII[J]. Tumour Biol, 2017, 39(5): 1010428317706215. |